Navigation Links
Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
Date:8/20/2007

Medical Device Component Supplier Presents Today at Small Cap Financial

Conference

BETHEL, Conn., Aug. 20 /PRNewswire-FirstCall/ -- Memry Corporation (Amex: MRY), a leading provider of nitinol and polymer components to the medical device industry, announced today that unaudited preliminary results indicate revenue of approximately $13.1 million for the fourth fiscal quarter ended June 30, 2007, an increase of over 7% from the third quarter and down slightly from prior year results. For the fiscal year ended June 30, 2007 revenue is expected to be $51.7 million compared to $52.6 million in fiscal year 2006.

Memry Chief Executive Officer Robert Belcher said, "While we are disappointed in our full year revenue performance, we are pleased to report these preliminary financial results indicate a stronger fourth quarter than expected. We have been investing for several years in materials, technologies and processes to build our pipeline for the longer term. Our research and development initiatives are now helping us resume growth and we have begun to see the benefits of our investment in new capabilities and customer-sponsored development projects.

"We are encouraged with the revenue results achieved in the fourth quarter. On a comparative basis, nitinol revenue for the fourth quarter of fiscal 2007 has exceeded the fourth quarter revenue of fiscal 2006. In our polymer business, revenue is down versus the fourth quarter of fiscal 2006, which was an exceptionally strong quarter.

"On a sequential quarter basis, both our nitinol and polymer sales have resumed growth, with both segments reporting higher sales in the fourth quarter of fiscal 2007 than in the third quarter
'/>"/>

SOURCE Memry Corporation

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related biology technology :

1. Trouble-shooting: Misincorporation or low fidelity
2. Roche Diagnostics Corporation
3. Roche Diagnostics Corporation
4. Promega Corporation: Wisconsins quiet innovator
5. Giuliani will keynote RedPrairie Corporations user conference
6. Madison Development Corporation makes loans to three area companies
7. Corporations and blogging
8. Metavante acquires Florida banking corporation
9. TriMas Corporations Cequent Group Acquires Chem-Chrome, Inc.
10. Speaker announces business members of IT Task Force
11. Doyle announces technology tax credits for Berbee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2015)...   University of Maryland (UM) Ventures and ... of an exclusive option by Biomecite Diagnostics for the ... diagnostics to detect inflammatory bowel diseases (IBD), such as ... Florian Fricke and James White developed ... of Maryland School of Medicine,s Institute for Genome Sciences ...
(Date:5/6/2015)... (PRWEB) May 06, 2015 Histogen, ... on the products of cells grown under simulated ... 105F immunomodulatory treatment candidate for melanoma during the ... taking place May 6-9, 2015 in Atlanta, GA. ... cells produce a soluble material with anti-oncologic properties, ...
(Date:5/5/2015)... 5, 2015 /PRNewswire/ - Aptose Biosciences Inc. (NASDAQ: APTO, TSX: ... for the three months ended March 31, 2015 and ... are in Canadian dollars. Effective July ... from May 31 to December 31. As a result ... is for the three months ended March 31, 2015, ...
(Date:5/5/2015)... DUBLIN , May 05, 2015 /PRNewswire/ ... ) has announced the addition of the ... report to their offering. Macromolecules ... acids undergo separation or are broken into ... biotechnological products. This separation requires various advanced ...
Breaking Biology Technology:Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 2Biomecite Diagnostics Signs Option Agreement with UM Baltimore to Develop Tools to Detect Inflammatory Bowel Diseases 3Novel Immunomodulatory Treatment Induces Apoptosis in Melanoma 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 2Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 3Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 4Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 5Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 6Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 7Aptose Biosciences Reports Results for the First Quarter Ended March 31, 2015 8Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2
... Syndax Pharmaceuticals, Inc. announced today that data ... entinostat, a novel, oral small molecule inhibitor of class ... in patients with relapsed or refractory Hodgkin,s lymphoma (HL).  ... 6:00 to 8:00 PM PT at the American ...
... ICBS Ltd., (OTCPK: ICBT), updates shareholders. As you ... we feel have the greatest chance of success. They are ... each instance, ICBS has funded the purchase of equipment and ... goals. We have paid for all of their expenses in ...
... 2011  CeNeRx BioPharma, Inc., a clinical stage company ... the central nervous system (CNS), today announced completion ... Soros Biopharmaceutical Fund, L Capital Partners, Pappas Ventures ... CeNeRx plans to use the proceeds to complete ...
Cached Biology Technology:Entinostat Demonstrates Activity in Hodgkin's Lymphoma 2Entinostat Demonstrates Activity in Hodgkin's Lymphoma 3Entinostat Demonstrates Activity in Hodgkin's Lymphoma 4Entinostat Demonstrates Activity in Hodgkin's Lymphoma 5ICBS, Update for Shareholders. 2ICBS, Update for Shareholders. 3CeNeRx BioPharma Completes $4.85 Million Financing 2CeNeRx BioPharma Completes $4.85 Million Financing 3
(Date:4/2/2015)... April 2, 2015 In ... by far outperforms the strongest competitors, showing outstanding ... accuracy, the system is capable of a throughput ... proves up to be ten times faster than ... runner-up performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... --  Medisafe ™, the leading global medication management platform ... and Android smartphones and tablets, announces today ... to allow patients to track and correlate their adherence ... will be able to visualize in real-time how taking ... as glucose levels and blood pressure. "Patients ...
(Date:3/24/2015)... Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) ... Recognition Market 2015-2019" report to their offering. ... to grow at a CAGR of 23.5 percent over ... present scenario and the growth prospects of the Global ... the market size, the report considers the revenue generated ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
... than boys. Every third child of school age prefers soft ... fish and do not think of themselves as being fussy ... taste differently.The findings of the world,s largest study so far ... and what they like have now been published. The study ...
... Society of Japan (PSJ) has chosen Springer to publish ... , starting in January 2009 with Volume 59, Number ... Society and Medical Tribune Co. Ltd. The journal ... includes such publications as Experimental Brain Research ...
... Medical Center have discovered that older people use their ... storing memories, particularly those associated with negative emotions. ... of Psychological Science , is a novel look ... Older adults, average age 70, and younger adults, average ...
Cached Biology News:Girls have superior sense of taste to boys 2Girls have superior sense of taste to boys 3Girls have superior sense of taste to boys 4Springer and the Physiological Society of Japan sign publishing agreement 2Old and young brains rely on different systems to remember emotional content 2
ANTI END CEL LUNG AG...
For the quantitative determination of canine Interleukin 10,(IL-10) concentrations in cell culture supernates, canine serum,and plasma....
EGTA, 50 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
RAT ANTI RAT RT1Au (CLASS I POLYMORPHIC) Immunogen: AO lymphoid cells...
Biology Products: